 |
|
Immune-Based, Targeted Therapy for Allergic Diseases
Marshall Plaut, MD
JAMA. 2001;286:3005-3006.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Allergic rhinitis is an inflammatory disorder characterized by upper airway symptoms, including nasal congestion, rhinorrhea, sneezing, and itching of the palate, and, in some patients, by conjunctivitis, otitis media with effusion, sinusitis, or asthma.1 The prevalence of allergic rhinitis, a common disease that affects approximately 9% to 22% of the US population,2-3 has increased substantially in the past 20 years.4 Symptoms of seasonal allergic rhinitis recur at times of the year corresponding to the appearance of airborne allergens such as pollens and mold spores. Some patients are symptomatic only during the pollen season while many others are allergic to multiple allergens or have a nonallergic component to their rhinitis so that they are symptomatic through much of the year.
One of the common causes of allergic rhinitis in the United States is ragweed.5-6 Ragweed is found east of the Rocky Mountains and typically produces pollen in August . . . [Full Text of this Article]
Author Affiliation: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
RELATED ARTICLE
Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis: A Randomized Controlled Trial
Thomas B. Casale, John Condemi, Craig LaForce, Anjuli Nayak, Michael Rowe, Marc Watrous, Margaret McAlary, Angel Fowler-Taylor, Amy Racine, Niroo Gupta, Robert Fick, Giovanni Della Cioppa, and for the Omalizumab Seasonal Allergic Rhinitis Trial Group
JAMA. 2001;286(23):2956-2967.
ABSTRACT
| FULL TEXT
|
